E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Subjects with Relapses and Refractory Peripheral T-Cell Lymphoma |
Sujetos con recaída o refractarias a limfoma de células T periférico |
|
E.1.1.1 | Medical condition in easily understood language |
lymphoma in the cases of previous treatment have failed |
Limfoma en el caso que los tratamientos anteriores hayan fallado |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the anti tumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with relapsed or refractory peripheral T-cell Lymphoma (PTCL) |
Determinar la actividad antitumoral en términos de tasa respuesta objeta (TRO) al tipifarnib en pacientes con recaída o refractarios a limfoma de células T periférico. |
|
E.2.2 | Secondary objectives of the trial |
To determine the anti tumor activity in terms of progression free survival ( PFS) and duration of response (DOR) of tipifarnib in subjects with relapsed or refractory PTCL |
Determinar la actividad antitumoral en términos de progresión libre de enfermedad (PFS) y duración de la respuesta (ORR) al tipifarnib en pacientes refractarios o con recaída a limfoma de células T periférico |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subject has a diagnosis of PTCL according to the most recent edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic or Lymphoid Tissues as follows: a. Anaplastic large cell lymphoma (ALCL), ALK positive b. ALCL, ALK negative c. Angioimmunoblastic T-cell lymphoma (AITL) d. Enteropathy-associated T-cell lymphoma e. Extranodal natural killer (NK) T-cell lymphoma, nasal type f. Hepatosplenic T-cell lymphoma g. Peripheral T-cell lymphoma, no otherwise specified (NOS) h. Subcutaneous panniculitis-like T-cell lymphoma |
El sujeto tiene un diagnóstico de linfoma de células T periférico (PTCL) de acuerdo con la edición más reciente de la Organización Mundial de la Salud (OMS) de los tumores de tejidos linfoides o hematopoyéticos de la siguiente manera: a. Linfoma anaplásico de células grandes (LACG), ALK positivo b. LACG, ALK negativo c. Linfoma angioinmunoblástico de células T (AITL) d. Linfoma de células T asociado a enteropatía e. Linfoma extranodal de células T y de células (NK), tipo nasal f. Linfoma Hepatosplénico de células T g. Linfoma periférico de células T, sin alguna otra caracterización h. Linfoma de apariencia paniculítica subcutáneo de células T. |
|
E.4 | Principal exclusion criteria |
1. Diagnosis of any of the following: a. Precursor T-cell lymphoma or leukemia b. Adult T-cell lymphoma/leukemia (ATLL) c. T-cell prolymphocytic leukemia d. T-cell large granular lymphocytic leukemia e. Primary cutaneous type anaplastic large cell lymphoma Page 6 of 58 f. Mycosis fungoide/Sezary syndrome |
Diagnóstico de alguna de las siguientes:
a. Precursor de linfoma de células T o leucemia b. Linfoma/Leucemia de células T del adulto c. Leucemia prolinfocitica de células T d. Leucemia linfocítica granular de células T grandes e. Limfoma anaplásico de células grandes, tipo cutáneo f. Micosis fungoide/ Síndrome Sézary |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Response assessments determined by IWC and/or mSWAT |
Enfermedad medible secos IWC y/o mSWAT |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At screening (4 weeks before the first study drug administration), at the end of cycle 2, 4, 6 and then approximately 9 week cycle 9, 12, 15, and other thereafter until disease progression |
Durante la visita selección ( 4 semanas antes de la primera dosis), al final del ciclo 2, 4 y 6 , luego aproximadamente cada 9 semanas , ciclo 9, 12, 15 y siguientes hasta progresión enfermedad |
|
E.5.2 | Secondary end point(s) |
SAEs evaluated according to NCI CTCAE v.4.03 |
Acontecimientos Adversos graves evaluados según CTCAE v4.03 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Comprehensive assessment of any apparent toxicity experienced by the subject will be performed throughout the course of the trial (at each study visit and as clinically needed), from the time of the subject's signature of informed consent until 30 days from the final administration of the trial treatment or immediately before initiation of any other anticancer therapy, whichever comes first |
Evaluación de cualquier toxicidad aparente ocurrida al sujeto durante el transcurso del ensayo ( en cada visita de estudio y como sea necesario clínicamente), desde la firma del consentimiento informado hasta 30 días después de la última dosis de tratamiento, o inmediatamente antes de cualquier otro tratamiento antitumoral |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 7 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of this clinical study is defined as the day when the last remaining study subject in the trial completes the last Follow-up assessment no later than 12 months after the last study subject is enrolled in the study. Provisions will be made for the continuation of study treatment in patients who demonstrate objective response or disease stabilization and manageable toxicity beyond the end of the study, e.g. a single patient treatment protocol |
El final del ensayo clínico se define como el día en que el último sujeto completa la visita de seguimiento no después de 12 meses después que el último sujeto del estudio haya sido incluido en el estudio. Se ha considerado la continuidad del tratamiento del estudio en los pacientes que demuestren respuesta objetiva o estabilización de la enfermedad y toxicidad manejable más allá del final del estudio, por ejemplo, como un único protocolo de tratamiento al paciente. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |